By Dr Nicola Davies
Rare forms of multiple sclerosis (MS) exhibit certain atypical imaging characteristics that are absent in typical MS, although the clinical features of these variants are similar to typical MS. Although the rarity of these diseases restricts the research and development of disease-specific therapies, some progress has been made. In this exclusive article, Dr Davies investigates this progress.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze